| scholarly article | Q13442814 |
| P50 | author | Naveed Zafar Janjua | Q39716263 |
| James A Dickinson | Q42422634 | ||
| Patrick Tang | Q51082965 | ||
| Travis Salway Hottes | Q55807402 | ||
| Natasha Sarah Crowcroft | Q61100890 | ||
| Yan Li | Q69032212 | ||
| Nathalie Bastien | Q69032280 | ||
| Hugues Charest | Q86870110 | ||
| Gaston De Serres | Q86870133 | ||
| Jonathan B Gubbay | Q87716515 | ||
| Danuta M. Skowronski | Q111259505 | ||
| Martin Petric | Q114718266 | ||
| Kevin Fonseca | Q114718268 | ||
| Trijntje L Kwindt | Q114718277 | ||
| P2860 | cites work | Estimates of pandemic influenza vaccine effectiveness in Europe, 2009-2010: results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) multicentre case-control study | Q21144621 |
| Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study | Q28751886 | ||
| Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. | Q30357784 | ||
| Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada | Q30388012 | ||
| Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. | Q30389024 | ||
| Protective effect of single-dose adjuvanted pandemic influenza vaccine in children | Q30391363 | ||
| Vaccine effectiveness in pandemic influenza - primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. | Q30391398 | ||
| Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons | Q33541763 | ||
| Field evaluation of vaccine efficacy | Q34193122 | ||
| An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination | Q41024287 | ||
| Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. | Q48071872 | ||
| Pooling of confounders did not induce residual confounding in influenza vaccination studies. | Q53056615 | ||
| Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season | Q83152060 | ||
| Effectiveness of vaccine against medical consultation due to laboratory-confirmed influenza: results from a sentinel physician pilot project in British Columbia, 2004-2005 | Q83273637 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Canada | Q16 |
| vaccine | Q134808 | ||
| pandemic | Q12184 | ||
| P304 | page(s) | c7297 | |
| P577 | publication date | 2011-02-03 | |
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. | |
| P478 | volume | 342 |
| Q47843797 | A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season |
| Q37976540 | Adjuvanted influenza vaccines |
| Q30411303 | Assessment of the variability in influenza A(H1N1) vaccine effectiveness estimates dependent on outcome and methodological approach |
| Q37033053 | Autoimmune Variant PTPN22 C1858T Is Associated With Impaired Responses to Influenza Vaccination |
| Q56561344 | Avian Influenza A Virus Pandemic Preparedness and Vaccine Development |
| Q47613621 | Beyond Antigenic Match: Possible Agent-Host and Immuno-epidemiological Influences on Influenza Vaccine Effectiveness During the 2015-2016 Season in Canada |
| Q35091073 | Comparison of the epidemiology of laboratory-confirmed influenza A and influenza B cases in Manitoba, Canada |
| Q37976539 | Correlates of vaccine protection from influenza and its complications |
| Q30413695 | Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion |
| Q30352405 | Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. |
| Q37912503 | Different influenza vaccine formulations and adjuvants for childhood influenza vaccination |
| Q30353821 | Differential influenza H1N1-specific humoral and cellular response kinetics in kidney transplant patients. |
| Q30419896 | Effectiveness of 1 dose of influenza A (H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 infection among school-aged children in maine |
| Q30235245 | Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis |
| Q57210380 | Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: A test-negative case control study |
| Q34707079 | Effectiveness of MF59™ adjuvanted influenza A(H1N1)pdm09 vaccine in risk groups in the Netherlands |
| Q30356962 | Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada. |
| Q30367263 | Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland. |
| Q30419503 | Effectiveness of the monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine against hospitalization in children because of influenza |
| Q30404419 | Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009-2010: cohort and case-control study. |
| Q55114818 | Effects of pre-existing orthopoxvirus-specific immunity on the performance of Modified Vaccinia virus Ankara-based influenza vaccines. |
| Q30408691 | Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis |
| Q34550913 | Estimating the influenza vaccine effectiveness against medically attended influenza in clinical settings: a hospital-based case-control study with a rapid diagnostic test in Japan |
| Q42270731 | Evaluation and sensitivity analysis of the effectiveness of unadjuvanted A(H1N1)pdm09 vaccine in hospital workers using multi-center cohort study in Korea |
| Q30393380 | Evaluation of Influenza Vaccination Efficacy: A Universal Epidemic Model. |
| Q35939390 | Evaluation of Microflow Digital Imaging Particle Analysis for Sub-Visible Particles Formulated with an Opaque Vaccine Adjuvant |
| Q30382343 | Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets. |
| Q30402693 | Field effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 A(H1N1) influenza: estimations from surveillance data in France |
| Q37619140 | From discovery to licensure, the Adjuvant System story |
| Q33891510 | Geographical heterogeneity and influenza infection within households |
| Q30412103 | H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study |
| Q91774677 | Health outcomes of young children born to mothers who received 2009 pandemic H1N1 influenza vaccination during pregnancy: retrospective cohort study |
| Q30413786 | Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: systematic review and meta-analyses. |
| Q30392456 | Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice |
| Q56562454 | Induction of Cross-Clade Antibody and T-Cell Responses by a Modified Vaccinia Virus Ankara-Based Influenza A(H5N1) Vaccine in a Randomized Phase 1/2a Clinical Trial |
| Q42242172 | Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine |
| Q30411868 | Influenza vaccination coverage rate in children: reasons for a failure and how to go forward |
| Q30354181 | Influenza vaccination in India: position paper of Indian Academy of Pediatrics, 2013. |
| Q34850986 | Influenza vaccine effectiveness against hospitalisation with confirmed influenza in the 2010-11 seasons: a test-negative observational study |
| Q36956943 | Influenza vaccine effectiveness in the community and the household |
| Q41045747 | Influenza vaccines differentially regulate the interferon response in human dendritic cell subsets. |
| Q30367695 | Influenza vaccines: a moving interdisciplinary field. |
| Q27027029 | Influenza virus vaccines: lessons from the 2009 H1N1 pandemic |
| Q38415770 | Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season |
| Q42237299 | Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada s sentinel surveillance network, January 2014. |
| Q30373642 | Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children. |
| Q35130915 | Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses |
| Q53091538 | Magnitude of potential biases in a simulated case-control study of the effectiveness of influenza vaccination. |
| Q42541370 | Mandatory vaccination |
| Q59358635 | Modelling the population effectiveness of the national seasonal influenza vaccination programme in Scotland: the impact of targeting all individuals aged 65 years and over Flu Vaccination Programme Effectiveness |
| Q38619090 | Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo. |
| Q36565552 | Nanoemulsion nasal adjuvant W₈₀5EC induces dendritic cell engulfment of antigen-primed epithelial cells |
| Q30421549 | PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries |
| Q51165360 | Patterns of spread of influenza A in Canada. |
| Q30421507 | Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients. |
| Q34778408 | Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review |
| Q30364076 | Pre- and postpandemic estimates of 2009 pandemic influenza A(H1N1) seroprotection to inform surveillance-based incidence, by age, during the 2013-2014 epidemic in Canada. |
| Q30417417 | Prospective hospital-based case-control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009-2010 using matched hospital and test-negative controls |
| Q30406933 | Rapid assessment of influenza vaccine effectiveness: analysis of an internet-based cohort |
| Q30360483 | Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. |
| Q43978729 | Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011. |
| Q37998104 | Risk factors and effectiveness of preventive measures against influenza in the community |
| Q30367259 | Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. |
| Q30414902 | Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study |
| Q30369467 | Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials. |
| Q98727086 | Selection bias may explain the relationship between coronavirus diagnosis and the odds of prior influenza vaccination |
| Q90692852 | The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology |
| Q30427049 | The first, second and third wave of pandemic influenza A (H1N1)pdm09 in North Denmark Region 2009-2011: a population-based study of hospitalizations |
| Q30418277 | The potential effect of temporary immunity as a result of bias associated with healthy users and social determinants on observations of influenza vaccine effectiveness; could unmeasured confounding explain observed links between seasonal influenza v |
| Q30224656 | Two years after pandemic influenza A/2009/H1N1: what have we learned? |
| Q30432474 | Using a Dynamic Model to Consider Optimal Antiviral Stockpile Size in the Face of Pandemic Influenza Uncertainty |
| Q30410112 | Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010. |
| Q30410632 | Vaccination against 2009 pandemic H1N1 in a population dynamical model of Vancouver, Canada: timing is everything |
| Q30409727 | Vaccine effectiveness in preventing influenza hospitalizations in Navarre, Spain, 2010-2011: cohort and case-control study |
| Q38803189 | Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies |
Search more.